Figure 4.

Ability of dopamine transporter (DAT) imaging to identify subjects who experience a clinically important worsening of the harmonized motor scores. Clinically important worsening or clinically important difference (CID) was defined as change from baseline in the harmonized motor scores of at least 3 points at 24 months. DAT‐based enriched trial is one that includes only DAT‐deficit subjects. Solid arrows mean that criteria are being applied.

PD, Parkinson disease; SWEDD, subjects without evidence of DAT deficit.